Dr. Luke on Combining an IDO Inhibitor With Nivolumab in Advanced Cancers
Jason J. Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses a study evaluating the IDO1 inhibitor BMS-986205 as a monotherapy and in combination with nivolumab in patients with advanced cancers.
Jason J. Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses a study evaluating the IDO1 inhibitor BMS-986205 as a monotherapy and in combination with nivolumab (Opdivo) in patients with advanced cancers during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.
Luke explains that the IDO pathway is an important immunosuppressive pathway that is upregulated in the context of a productive interferon gamma-associated tumor microenvironment. That was original thought to be PD-L1 alone, but we are learning that most often when PD-L1 is upregulated, IDO is upregulated as well, and can act as a secondary immunologic checkpoint to slow down T cells, even if you block PD-1, he says. There is a lot of interest in combining these approaches to augment immunotherapy.
